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Alzheimer's disease (AD) is characterized by aggregation of amyloid beta (Ab) into insoluble plaques.
Intermediates, Ab oligomers (Abo), appear to be the mechanistic cause of disease. The de facto PET AD
ligand, [11C]PIB, binds and visualizes Ab plaque load, which does not correlate well with disease severity.
Therefore, ﬁnding a dynamic target that changes with pathology progression in AD is of great interest.
Abo alter synaptic plasticity, inhibit long-term potentiation, and facilitate long-term depression; key
mechanisms involved in memory and learning. In order to convey these neurotoxic effects, Abo requires
interaction with the metabotropic glutamate 5 receptor (mGluR5). The aim was to investigate in vivo
mGluR5 changes in an Ab pathology model using PET. Wild type C57/BL6 (wt) and AbPP transgenic mice
(tg-ArcSwe), 4, 8, and 16 months old, were PET scanned with [11C]ABP688, which is highly speciﬁc to
mGluR5, to investigate changes in mGluR5. Mouse brains were extracted postscan and mGluR5 and Ab
protoﬁbril levels were assessed with immunoblotting and ELISA respectively. Receptor-dense brain re-
gions (hippocampus, thalamus, and striatum) displayed higher [11C]ABP688 concentrations corre-
sponding to mGluR5 expression pattern. Mice had similar uptake levels of [11C]ABP688 regardless of
genotype or age. Immunoblotting revealed general decline in mGluR5 expression and elevated levels of
mGluR5 in 16 months old tg-ArcSwe compared with wt mice. [11C]ABP688 could visualize mGluR5 in the
mouse brain. In conclusion, mGluR5 levels were found to decrease with age and tended to be higher in
tg-ArcSwe compared with wt mice, however these changes could not be quantiﬁed with PET.
© 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Ever since the ﬁrst diagnosis of Alzheimer's disease (AD), the
three histological hallmarks (plaques, neuroﬁbrillary tangles and
neurodegeneration) underlying the changes in memory and
behavior have been studied intensively. The amyloid beta (Ab)
protein, themain component of plaques, has been a key target since
its discovery (Masters et al., 1985). The amount of insoluble Ab ﬁ-
brils, i.e. the main component of plaques, does not correlate well
with disease progression. Instead, accumulating evidence indicate
that the level of soluble Ab oligomers (Abo) and protoﬁbrils
correlate with disease stage (McLean et al., 1999; N€aslund et al.,
2000). Also post-mortem studies have found higher Ab oligomer-yv€anen).
r Ltd. This is an open access articleto-plaque ratios in demented patients than in non-demented pa-
tients with Ab plaque pathology (Esparza et al., 2013; Santos et al.,
2012).
Monitoring disease progression over time is not feasible with
conventional histological methods, as these are performed on post-
mortem tissue samples. Nor do biomarkers in CSF such as Ab42, tau
or phosphor-tau change in relation to disease progression
(Grossman et al., 2005; Lin et al., 2009; Mehta et al., 2001; Wallin
et al., 2011). This has led to the development of imaging based
techniques to observe AD pathology in vivo. [11C]PIB is the most
widely used positron emission tomography (PET) radioligand for
visualizing Ab plaque load in the human brain in vivo (Klunk et al.,
2004). The downside to this radioligand and other PET-ligands
targeting ﬁbrillar amyloid is the inability to quantify disease pro-
gression as their signal, in line with CSF biomarkers, saturates
rapidly, leaving it therefore mainly suitable for a binary assessment
of Ab plaque presence (Engler et al., 2006).under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/
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PET radioligands for measuring disease stage severity. Further,
more dynamic markers may also be used to quantify the efﬁcacy of
novel treatments. A prerequisite to do this is to ﬁnd a target (i.e. a
receptor or a protein) of which the expression would change with
disease severity.
One of the earliest signs of AD pathology is an impairment of
memory, possibly due to synaptic dysfunction and loss caused by
Abo (Klein, 2001). Abo also alter synaptic plasticity, inhibit long-
term potentiation (LTP) (Nomura et al., 2012; Walsh et al., 2002);
and facilitate long-term depression (LTD) (Wang et al., 2002). The
mechanisms by which Abo initiate pathology involve binding to
excitatory synapses and disrupting synaptic function (Lacor et al.,
2004).
The metabotropic glutamate receptor 5 (mGluR5) is a post-
synaptically expressed G-protein coupled receptor involved in
Ca2þ regulation (Abe et al., 1992), and plays an essential role in
modulating synaptic strength in the adult brain (Jong et al., 2009).
Presenilin-1 (PS1) deﬁcient neurons have decreased glutamate
uptake and lower cell surface expression of neuronal glutamate
receptor EEAC1 compared to wild type (wt) neurons and similar
effects are seen with gamma-secretase inhibitor treatment (Yang
et al., 2004). Renner and colleagues reported an interaction be-
tween Abo and mGluR5, whereby the Ab oligomers perturb syn-
aptic functioning by binding to them. Following the interaction
with the synapse by the Abo, individual mGlu5 receptors are hin-
dered in their diffusion laterally and cluster; which leads to
elevated intracellular calcium and synaptotoxicity (Renner et al.,
2010). At the post-synaptic density, Abo bind with high afﬁnity to
Cellular Prion Protein (PrPC) (Lauren et al., 2009). This pathology
causing complex requires the presence of mGluR5 in order for Abo-
PrPC to interact with Fyn and mediate an increase of intracellular
calcium (Um et al., 2013). In a transgenic mouse model over-
expressing amyloid b protein precursor (AbPP), mGluR5 levels were
increased in the CA3 region of the hippocampus and toxicity was
caused by increased calcium ﬂux (Overk et al., 2014). Hamilton et al.
crossed the AbPPSwe/PS1DE9 AD mouse model with an mGluR5 null
mouse line, and the genetic deletion of mGluR5 reversed the spatial
memory deﬁcit observed in AbPPSwe/PS1DE9 mice; furthermore, the
AD mice showed increased mGluR5 expression on the cell surface,
but no increase in total levels in brain lysate (Hamilton et al., 2014).
Previously however, an increase in mGluR5 expression by Ab has
been reported, but this was in cultured astrocytes (Casley et al.,
2009). Antagonists for mGluR5 also reversed learning and mem-
ory deﬁcits in AD mouse models, and synaptic markers recovered
after a 10-day treatment with an mGluR5 antagonist (Um et al.,
2013). In AD patients, metabotropic glutamate receptor binding
was decreased in frontal cortex directly correlating to Braak stage
progression (Albasanz et al., 2005). Altogether mGluR5 seems to
play an integral role in the development of Abo pathology, and may
prove to be a potential biomarker for disease progression.
The aim of the present studywas to investigate the expression of
mGluR5 during disease progression in a transgenic mouse model
overexpressing human AbPPArcSwe (tg-ArcSwe) (Lord et al., 2006). In
addition to in vitro quantiﬁcation of mGluR5 using different
immunoassay techniques, expression and function of mGluR5
during disease progression was investigated in vivo using [11C]
ABP688, a novel PET ligand with high afﬁnity and selectivity for
mGluR5 (Ametamey et al., 2006).
2. Material and methods
2.1. Animals
All procedures described in this paper were approved by theUppsala County Animal Ethics board (#C216/11, #C110/11 and
#C17/14), following the rules and regulations of the Swedish Ani-
mal Welfare Agency and were in compliance with the European
Communities Council Directive of 22 September 2010 (2010/63/
EU). The tg-ArcSwe model (maintained on a C57BL/6 background)
harboring the Arctic (AbPP E693G) and Swedish (AbPP KM670/
671NL) mutations was used. Tg-ArcSwe mice show elevated levels
of soluble Ab protoﬁbrils already at a very young age and abundant
and rapidly developing plaque pathology starting at around 6
months of age (Lord et al., 2009, 2006; Philipson et al., 2009). Wild
type littermates were used as control animals (wt). Animals were
housed with ad libitum access to food and water in rooms with a
maintained consistent temperature and humidity in an animal fa-
cility at Uppsala University.
2.2. Synthesis of [11C]ABP688 ((E)-[O-methyl-11C]ABP688) for
injection
ABP688 (3-((6-methylpyridin-2-yl)ethynyl)cyclohex-2-en-1-
one O-methyl oxime) and O-desmethyl ABP688 (3-((6-
methylpyridin-2-yl)ethynyl)cyclohex-2-en-1-one oxime) as a 12:1
mixture of E/Z enantiomers were obtained from ABX (Radeberg,
Germany). All reagents and solvents used in the radiosyntheses
were supplied by Aldrich and used as received. The production of
[11C]ABP688 was performed according to a previously published
method with modiﬁcations (Ametamey et al., 2006).
Cyclotronproduced [11C]carbondioxidewas transferred inhelium
gas and trapped in a solution of LiAlH4 (300 mL, 0.2 M) in tetrahy-
drofuran. The solvent was removed under a stream of nitrogen
(160 mL/min) while heating the vessel at 130 C during 1.5 min. Hy-
driodic acidwas added (1mL, 57%) and the formed [11C]methyl iodide
transferred in nitrogen gas (10 mL/min) over a phosphorous pent-
oxide column and bubbled into a solution of desmethyl ABP688
(1.0 mg, 4.4 mmol) and NaOH (3.0 mL, 5.0 M, 15 mmol) in anhydrous
dimethylformamide (250 mL). The reaction mixture was heated at
90 C for 5 min, diluted with water (500 mL) and the product was
puriﬁed by semi-preparative radio/UV-HPLC (Column: Phenomenex
Luna, 10m, C18(2), 250  10 mm; Eluent: ammonium formate pH 3.5
(50 mM)/acetonitrile 55/45; 5 mL/min). [11C]ABP688 eluted at
12.7 min and the collected fraction was diluted with water (20 mL)
andpassedovera solidphaseextraction (SPE) cartridge (Sep-Pak tC18
Plus Light Cartridge) followed by a wash with 20% ethanol in water
(20 mL) to remove the HPLC mobile phase and polar impurities. The
product (3.1± 0.7 GBq)was eluted from the SPE-cartridgewith 99.5%
ethanol (0.2 mL) and reformulated in phosphate buffered saline pH
7.4 (2 mL) and Kleptose® (0.1 mL, hydroxypropyl betacyclodextrin
300 mg/mL in sodium chloride 9 mg/mL). The synthesis time from
end of radionuclide production to formulated product was approxi-
mately 40min. The radiochemical purity was 97.4 ± 0.9% as assessed
by analytical radio/UV-HPLC (Column: Phenomenex Chromolith
Performance RP-18e, 100 4.6 mm; Eluent: ammonium formate pH
3.5 (50 mM)/acetonitrile 55/45; 5 mL/min). The identity of the
product was conﬁrmed by comparing the retention time (5.9 min)
with authentic ABP688. The speciﬁc radioactivity was determined by
the same HPLC method as used for the assessment of radiochemical
and chemical purity.
2.3. PET
PET was performed in mice using a preclinical Triumph micro
LabPet/CT. The animals (wt C57BL/6 and transgenic ArcSwe strain
at either 4, 8 or 16 months of age) were anesthetized with iso-
ﬂurane prior to administration of [11C]ABP688 (mean injected ac-
tivity of 9.7 ± 5.7 MBq, mean speciﬁc activity of 19.9 ± 25.0 GBq/
mmol at time of injection, transgenic and control micewere injected
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jection. Scan duration was 30 min, and breathing frequency was
monitored and maintained at 50e70 breaths per minute. Mice
were scanned between 10 a.m.e2 p.m. PET data were acquired in
list mode and reconstructed in user-deﬁned time frames (6 $ 10 s, 3
$ 60 s, 5 $ 5 min) using a MLEM 2D algorithm. Following the PET
scan, a CT scan was performed (Field of View: 80 mm).
2.4. PET analysis
Image ﬁles were evaluated by region-of-interest (ROI) analysis
using AMIDE (Loening and Gambhir, 2003). ROIs were drawn
manually once based on the M. Mirrione T2-weighted MRI VOI
template found in Pmod (PMOD Technologies Ltd., Zürich,
Switzerland), then manually co-registered with each study using
the CT as reference (Ma et al., 2005; Mirrione et al., 2007). Regional
time-activity curves (TAC) based on ROIs were calculated for the
following brain regions: hippocampus (20.4 mm3), striatum
(20.2 mm3), whole brain (312.4 mm3), and cerebellum (46.5 mm3).
Regional BPnd were obtained with Pmod using the simpliﬁed
reference tissue model (SRTM) with the cerebellum as reference
region (Elmenhorst et al., 2010; Lammertsma and Hume, 1996).
2.5. Brain extraction and ex vivo studies
Following the PET scan, animals were anesthetized with iso-
ﬂurane (3.5%) and intracardially perfused with 50 mL of 37 C
physiological saline. After extracting the brain, hemispheres were
divided: The left hemisphere was snap frozen with dry ice and
stored at 70 C, and the right hemisphere was left in 4% para-
formaldehyde in PBS for 24 h, followed by a sucrose gradient im-
mersion. The left hemisphere was then homogenized with a tissue
grinder with teﬂon pestle (2$10 strokes) in a 1:5 tissue:Tris-acetate
buffer (50 mM, pH 7.4) weight:volume ratio with complete prote-
ase inhibitors (Roche).
In addition, radioactivity in blood samples and in the frozen
brain hemisphere were measured with a g-counter (1480 Wizard,
Wallac Oy, Turku, Finland) as follows:% of injected dose
gbrain
¼ measured radioactivity per gram tissue ðor bloodÞ
injected activity
% SUVbrain ¼
measured radioactivity per gram tissue ðor bloodÞ
injected radioactivity per gbodyweight
*100In order to obtain membrane fractions, 300 mL of sample ho-
mogenate was puriﬁed by differential centrifugation. Homogenate
was spun down at 1000  g for 10min. Supernatants were then
centrifuged at 14,000 g for 20 min at 4 C. Pellet (P2) was deﬁned
as the crude synaptosomal fraction (Menard and Quirion, 2012),
resuspended in 300 mL TBS, and then used for immunoblotting.2.6. Immunoblotting
The P2 sample (15 mL) was incubated with lithium dodecylsulfate sample buffer at 70 C for 10 min, then loaded and run on
pre-cast 4e12% Bolt™ Bis-Tris gels (Life Technologies) at 200 V for
22 min. After transfer using Bolt® Mini Blot Modules (Life Tech-
nologies) onto 0.45 mm PVDF Immobilon® -FL transfer membranes,
theywere left incubating in Odyssey® Blocking Buffer (TBS) (LI-COR
Biosciences, P/N 927e50000) overnight at 4 C. Membranes were
incubated for 1 h at RT with the following primary antibodies: a-
mGluR5 (abcam [EPR2425Y] ab76316, 1:5000, 0.026 mg/mL) and a-
GAPDH (abcam [6C5] ab8245, 1:10,000, 0.2 mg/mL). After primary
antibody incubation, membranes were washed with TBS-T, and
secondary antibodies were applied for 1 h at RT (Odyssey goat a-
mouse IgG [H þ L] 680, 1:25,000, 0.04 mg/mL; and a-rabbit IgG
[H þ L] 800, 1:20,000, 0.05 mg/mL DyLight™). All antibodies were
diluted in blocking solutionþ TBS-T. Membraneswerewashedwith
TBS-T and imaged using the Licor Odyssey Sa Infrared imaging
system. Band densities were obtained with Image Studio Lite.
2.7. Protoﬁbril ELISA
Ab protoﬁbril levels in brain homogenate were measured as
previously described (Englund et al., 2007; Sehlin et al., 2016). In
brief, plates coated overnight with 200 ng/well mAb158 and then
blocked with 1% BSA in PBS, were incubated with TBS extract (1:25)
at RT for 2 h; followed by detection with biotinylated mAb158
(0.5 mg/mL), and SA-HRP (1:2000, Mabtech AB). Signal was devel-
oped with K blue aqueous TMB substrate (Neogen Corp., Lexington,
KY, USA) and development was halted by adding sulfuric acid.Wells
were then read with a spectrophotometer set to 450 nm.
2.8. Immunoﬂuorescence
The right hemisphere was cut into 20 mm thick sagittal sections
in a cryostat and mounted onto Superfrost® Plus glass slides
(Menzel-Glaser, Germany). Sections were rinsed in PBS and then
incubated with 5% normal goat serum (Vector Laboratories Inc.)
and 0.1% Triton X-100 in PBS. This was followed by an overnight
incubation at 4 C with mouse a-GFAP (1:400, G3893, Sigma-
Aldrich) and rabbit a-mGluR5 (1:200, [EPR2425Y] ab76316,abcam). After a series of PBS washes, slides were incubated with
goat a-mouse AF488 (1:500, A11001, Life Technologies) and goat a-
rabbit AF555 (1:300, A21429, Life Technologies) for 1 h at room
temperature. The sections were then mounted with DAPI contain-
ing Vectashield (Vector Laboratories Inc.) and left to air dry in the
dark.2.9. Statistics
The result values are given as mean ± s.e.m. Data were analyzed
Scheme 1. Synthesis of [11C]ABP688.
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post hoc Tukey's if there was signiﬁcance. Variance was assumed to
be equal between groups.
3. Results
3.1. [11C]ABP688 synthesis
The synthesis of [11C]ABP688 was performed according to a
previously published method with modiﬁcations (Ametamey et al.,
2006), Scheme 1. During puriﬁcation E and Z-enantiomers of [11C]
ABP688 were observed as two separated peaks on the preparative
HPLC chromatogram. The E/Z-ratio corresponded to the ratio in the
starting material, approximately 12:1. After the puriﬁcation, [11C]
ABP688 was obtained as a single E-enantiomer and the product
solution did not contain detectable amounts of the starting mate-
rial desmethyl ABP688. Radiolabelled impurities were formed
when the HPLC solvent was removed using rotary evaporation.
Instead [11C]ABP688 was reformulated using solid phase extraction
which included washing with 20% ethanol to remove residual polar
impurities. A solution of [11C]ABP688 ready for injection containing
3.1 ± 0.7 GBq was obtained 40 min after the end of the radionuclide
production. The radiochemical purity was 97.4 ± 0.9%.
3.2. [11C]ABP688 uptake in brain
To investigate mGluR5 distribution in the brain, wt and tg-Fig. 1. . [11C]ABP688 signal in mouse brain visualized with PET of (a) a typical brain distribut
co-injected with an excess of unlabeled ABP688.ArcSwe mice were administered with [11C]ABP688 and PET scan-
ned for 30min. A typical distribution patternwith high signal in the
hippocampus is shown in Fig. 1a, corresponding to an earlier vali-
dation study performed in rats (Elmenhorst et al., 2010). When
excess of isotopically unmodiﬁed (unlabeled) ABP688 was co-
injected with [11C]ABP688, the distinctive pattern of these recep-
tor rich regions disappeared (Fig. 1b).
To investigate age and genotype-dependent changes in receptor
binding, PET data was quantiﬁed as nondisplaceable binding po-
tential (BPnd) in several regions known for high mGluR5 expression
in the brain by using the simpliﬁed tissue referencemodel, with the
cerebellum as reference region (Fig. 2). The regions of interest were
hippocampus (a), thalamus (b), striatum (c), and the whole brain
excluding the cerebellum (d). The BPnd in the mGluR5 rich regions
hippocampus, thalamus, and striatum were higher than in the
whole brain. No effect of genotype on BPnd in the brain was
observed. However younger animals appeared to have slightly
higher BPnd in the thalamus than older animals (observed trend,
p ¼ 0.10).
3.3. Ex vivo radioactivity
The radioactivity in brain (Fig. 3 a-c) and blood (d-e) tissue
isolated after the PET scan was measured, and the brain-to-blood
concentration ratio of activity was found to be similar in all age
and genotype groups. The level of activity in the blood (measured
as % injected dose and SUV) remained consistent with age and
genotype as well.
3.4. Protoﬁbril levels in brain
As a measurement of Ab pathology, mouse brain tissue ho-
mogenate obtained from the PET scanned mice was analyzed with
ELISA for levels of soluble Ab protoﬁbrils. Tg-ArcSwemice displayed
accumulating Ab protoﬁbril levels as they aged (Fig. 4), while
background signals were found in wt mice of all ages.ion with high signal visible in the hippocampus, and (b) of a brain void of activity when
Fig. 2. . [11C]ABP688 BPnd values derived using SRTM with cerebellum as reference region. Regions of interest investigated were hippocampus (a), thalamus (b), striatum (c), and the
whole brain excluding the cerebellum (d). Receptor rich areas (hippocampus, p ¼ 0.0069; thalamus, p ¼ 0.0113; striatum, p < 0.0001) displayed higher BPnd values than the whole
brain region of interest. Statistical comparison of BPnd between regions was performed with one-way ANOVA with post hoc Tukey's, comparison between age and genotype within
regions was performed with two-way ANOVA with post hoc Tukey's. Number of animals per group: 4 m.o. tg-ArcSwe (n ¼ 5), 4 m.o. wt (n ¼ 6), 8 m.o. tg-ArcSwe (n ¼ 4), 8 m.o. wt
(n ¼ 5), 16 m.o. tg-ArcSwe (n ¼ 4), and 16 m.o. wt (n ¼ 6). Bars are displayed as mean ± standard error of the mean (s.e.m.).
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To investigate protein levels in the brain of tg-ArcSwe and wt
mice at different ages, we performed mGluR5 immunoblotting on
the brain tissue obtained post-scan, resulting in two main ﬁndings.
First, the amount of mGluR5 in wt mice decreased with age (Fig. 5).
This was not, however, found in tg-ArcSwe mice as they appeared
to express relatively constant mGluR5 levels at 4, 8, and 16 months.
Second, at all ages the tg-ArcSwe mice had higher mGluR5 levels
than wt mice, but this difference was only signiﬁcant in the 16
month group.
3.6. mGluR5 immunoﬂuorescence
In a separate group of animals, brain sections were co-
immunostained for mGluR5 and GFAP immunoﬂuorescence and
we investigated the CA3 region of the hippocampus, where previ-
ously it has been reported that mGluR5 is found to be upregulated
by Ab (Casley et al., 2009). Intensity quantiﬁcation of the mGluR5
signal found a signiﬁcant decrease in 12 month old wt mice
compared with age-matched tg-ArcSwe littermates, and 16 month
old wt mice. The mGluR5 signal also appeared to strongly coincide
with GFAP immunoﬂuorescence (Fig. 6).
4. Discussion
The present study aimed at investigating the changes in mGluR5
expression during disease progression in the tg-ArcSwe mouse
model of AD and to study whether these changes could be imaged
with PET radioligand [11C]ABP688 as a potential biomarker fordisease stage in AD. Previous studies have pointed towards an
involvement of mGluR5 in the synaptotoxicity caused by Abo (Lacor
et al., 2004; Nomura et al., 2012; Walsh et al., 2002; Wang et al.,
2002). To some extent, the present study conﬁrmed previous re-
ports of differences in mGluR5 expression between wt mice and
animals with Ab pathology.
Semi-quantitative analysis of mGluR5 expression using immu-
nohistochemistry also showed a signiﬁcant increase of mGluR5 in
the 12 months tg-ArcSwe mice compared to wt mice at 12 months
of age. Another interesting ﬁnding, also in line with previous
studies (Shrivastava et al., 2013), showed that mGluR5 tended to
cluster close to GFAP positive astrocytes. It has been reported that
astrocytic mGluR5 is upregulated by Ab (Casley et al., 2009).
Levels of mGluR5, quantiﬁed with immunoblotting, in mouse
brain were found to be higher in tg-ArcSwe mice than in wt mice.
An age-related decrease in mGluR5 level in wt mice was observed
with immunoblotting. Such a decrease was less apparent in tg-
ArcSwe mice. We speculate that the decrease observed in the wt
mice may be due synaptic loss in the hippocampus as part of age-
dependent decay in LTP and memory function (Bach et al., 1999;
Detoledo-Morrell et al., 1988). Although this process is likely to
also take place in the tg-ArcSwe brain, it is less evident from our
data possibly due to the overexpression and aberrant behavior of
mGluR5.
Tg-ArcSwe mice have elevated Ab protoﬁbril levels starting
already at an age of 4 months as found previously (Sehlin et al.,
2016). Plaque formation starts around 6 months and the pathol-
ogy develops fairly slowly compared to for example the most
commonly used AD mouse model, Tg2576 (Frautschy et al., 1998;
Lord et al., 2006). The increase in age-related Ab protoﬁbril
Fig. 3. Ex vivo measured radioactivity (mean ± s.e.m.) at 60 min post-injection in brain (aec) and blood (dee) quantiﬁed as their ratio, per cent of injected dose and SUV in samples
obtained from animals that had undergone PET scanning. No signiﬁcant differences were found with two-way ANOVA. Number of animals per group: 4 m.o. tg-ArcSwe (n ¼ 5), 4
m.o. wt (n ¼ 6), 8 m.o. tg-ArcSwe (n ¼ 4), 8 m.o. wt (n ¼ 5), 16 m.o. tg-ArcSwe (n ¼ 4), and 16 m.o. wt (n ¼ 6).
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levels, unlike in wt mice which have neither Ab protoﬁbrils nor
increased levels of mGluR5. It is possible that Ab protoﬁbril-
mediated clustering and accumulation of mGluR5 leads toFig. 4. ELISA for Ab protoﬁbril level in brain homogenate of 4, 8, and 16 month old tg-
ArcSwe and wt mice. ELISA signal in wild-type mice remains consistent and low as
they age, while tg-ArcSwe mice accumulate Ab PF with age. Already at 4 months tg-
ArcSwe mice have elevated levels compared with wt (p ¼ 0.0017). At 16 months of
age, tg-ArcSwe mice have signiﬁcantly higher protoﬁbril levels compared with age-
matched controls (p < 0.0001), 8 month old tg-ArcSwe (p < 0.0001), and 4 month old
tg-ArcSwe (p < 0.0001). Statistical analysis performed with two-way ANOVA with post
hoc Tukey's (**p < 0.01, ***p < 0.001, ****p < 0.001). Number of animals per group: n ¼ 4
(4 m.o. wt), n ¼ 7 (8 m.o. wt), n ¼ 4 (16 m.o. wt), n ¼ 4 (4, 8, and 16 m.o. tg-ArcSwe).elevated amounts of aberrantly functioning mGluR5, likely at the
post-synaptic density. This pool of mGluR5 then is part of the
pathological process, while in wt mice the age-related decrease
may be due to senescent synapse loss.
To our knowledge this is the ﬁrst study of mGluR5 in vivo in an
AD model. Previously, the interaction between mGluR5 and Ab has
been investigated in fmr-1 KOmice, in AbPPSwe/PS1, and in mGluR5
KO mice, however these were all ex vivo experiments (Hamilton
et al., 2014; Westmark and Malter, 2007). PET scans were per-
formed in 4, 8, and 16month old mice. We found higher BPnd in the
hippocampus, striatum, and thalamus than in the whole brain. This
goes in line with the expression pattern of mGluR5 in brain, which
has been reported to be highest in hippocampus, and moderate in
striatum and thalamus in human (Daggett et al., 1995). The binding
in these receptor rich areas could be blocked with unlabeled
ABP688 showing the speciﬁcity of the ligand.
The age and genotype differences assessed with immunoblot-
ting could not be visualized with PET in any of the regions studied.
Evidently, the Ab-related changes in mGluR5 are not reﬂected in
changes in BPnd. Potentially it may be that while receptor protein
levels are increased in tg-ArcSwe mice, ABP688 is unable to bind
this mGluR5 fraction because of mGluR5 clustering and formation
of complexes, as previously reported (Renner et al., 2010; Um et al.,
2013). Although 28 animals were scanned in total, they were for
analysis, divided into 6 groups and hence the fairly small group
sizes may also limit the possibility to observe small age and ge-
notype dependent differences.
Another explanation would be the limitation of performing PET
on small animals. One such limitation is the spatial resolution of
PET, as the mouse brain is small, and hence, the PET image
Fig. 5. a) Immunoblotting for GAPDH and mGluR5 in mouse brain lysate from the PET scanned animals. mGluR5 was visible in all animals at approximately 150 kDa. GAPDH
immunostaining was used as a loading control. b) Quantiﬁed mGluR5 density values corrected for loading control density (GAPDH). The mean density of the 4 month old wt group
was set as a baseline value, and the mean density values of the other groups were expressed as relative fold differences. Values per animal are averaged from 2 replicates. Two-way
ANOVA found a signiﬁcant age effect (p ¼ 0.0062), but post hoc correction for multiple comparisons with Tukey's found no signiﬁcant effect. Multiple t-tests between rows
(genotype groups) found a signiﬁcance (p < 0.05) between the 16 month old wt and 16 month old tg-ArcSwe animals. Number of animals per group: 4 m.o. tg-ArcSwe (n ¼ 4), 4 m.o.
wt (n ¼ 6), 8 m.o. tg-ArcSwe (n ¼ 4), 8 m.o. wt (n ¼ 5), 16 m.o. tg-ArcSwe (n ¼ 4), and 16 m.o. wt (n ¼ 4). Bars are displayed as mean ± standard error of the mean (s.e.m.).
Fig. 6. Left: Coronal section from a 4 months old wt mouse brain in the CA3 region of the hippocampus. GFAP (green) staining visualizes astrocytes, mGluR5 is shown in red. Arrow
points at a concentrated mGluR5 local intensity nearby an astrocyte (40 magniﬁcation). Right: Intensity quantiﬁcation of mGluR5 in the stratum radiatum of the hippocampus.
Transgenic ArcSwe mice have displayed higher mGluR5 intensity at 12 months of age compared to wt (p < 0.01). Bars are displayed as mean ± standard error of the mean (s.e.m.).
The number of animals per group was 5, except for the 12 month old tg-ArcSwe mice where n ¼ 4. (For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)
X.T. Fang et al. / Neuropharmacology 113 (2017) 293e300 299resolution (1e3 mm) may not be sufﬁcient. With the current low
resolution and small mouse brain, the partial volume effect also
plays an even larger role inmuddling activity levels. Furthermore, it
may be that changes in mGluR5 expression are too small to capture
with our current approach. Recently, it was found that using ultra-
high speciﬁc activity (3515e9620 GBq/mmol) improves visualiza-
tion and speciﬁc binding in a small-animal PET study for mGluR1 in
rat brain using [11C]ITMM compared with a more conventional SA
(74e174 GBq/mmol) (Yamasaki et al., 2016).
5. Conclusion
All in all, [11C]ABP688 appears to be a tracer with high speciﬁcity
for mGluR5. However, currently quantifying mGluR5 has been
proven to be difﬁcult in mice, at least in our tg-ArcSwe model used
here, although our data acquired from post-mortem tissue suggests
that Ab pathology may affect the levels of mGluR5. The study
showed that mGluR5 is likely to be upregulated in tg-ArcSwe mice
already before plaque formation, with the most pronounced
difference found between genotypes at 16 months of age.Nonetheless, [11C]ABP688 appears to be a speciﬁc tracer for imag-
ing of mGluR5 and we found typical tracer distribution corre-
sponding with regions known to be high in mGluR5 expression in
our transgenic and wt mice.
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